Cancel
Altay Therapeutics
See Linkedin
Altay Therapeutics Employees
7 people indexed:
-
q44@xjq45f4kw70j5gqgd.jxd Sign up to see email
-
w67v@1x1xwb3vk2w5jd8b5.dqw Sign up to see email
-
82g@4wfkgbgfj8xgq6747.079 Sign up to see email
-
n01nb@6zvqq18qqnx0qbfdw.w5q Sign up to see email
-
03204x@dqb4zb683zf9fg8wb.2vg Sign up to see email
-
369q@nfbwnw9vzd67wzjwf.873 Sign up to see email
-
60vqx@kqz9984b9f98v12jx.bfd Sign up to see email
Altay Therapeutics Company Information
Altay Therapeutics, previously known as Altay Therapeutics Inc, is a healthcare company located in San Carlos and South San Francisco, California. With a team of six members, Altay operates within the therapeutics sub-industry and participated in the Y-Combinator W20 batch. The company focuses on developing small molecule drugs to treat chronic liver diseases such as liver fibrosis and liver cancer, diseases affecting over 20 million Americans. Co-founder Dr. Osman Ozes, who previously led the development of Esbriet, the first FDA-approved therapy for lung fibrosis, brings significant expertise to the team, which collectively has over 70 years of experience in small molecule drug development. Altay Therapeutics has shown promising pre-clinical mouse data in several liver fibrosis models, demonstrating a reduction in fibrosis and a reversal of fibrotic tissue to normal tissue. The company aims to have a clinic-ready compound by the end of 2021 and to enter phase I clinical trials by mid-2022.
Report inaccurate information
Report inaccurate information
